Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O'Dwyer PJ. Denlinger CS, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):97-105. doi: 10.1007/s00280-009-1008-7. Epub 2009 May 5. Cancer Chemother Pharmacol. 2009. PMID: 19415281 Free PMC article. Clinical Trial.
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. Dotan E, et al. Among authors: denlinger cs. J Gastrointest Cancer. 2012 Dec;43(4):562-9. doi: 10.1007/s12029-012-9368-3. J Gastrointest Cancer. 2012. PMID: 22294255 Free PMC article. Clinical Trial.
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Zibelman M, et al. Among authors: denlinger cs. Invest New Drugs. 2015 Oct;33(5):1040-7. doi: 10.1007/s10637-015-0261-3. Epub 2015 Jun 20. Invest New Drugs. 2015. PMID: 26091915 Free PMC article. Clinical Trial.
Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors.
Chow LQ, Smith DC, Tan AR, Denlinger CS, Wang D, Shepard DR, Chaudhary A, Lin Y, Gao L. Chow LQ, et al. Among authors: denlinger cs. Cancer Chemother Pharmacol. 2016 Aug;78(2):433-41. doi: 10.1007/s00280-016-3098-3. Epub 2016 Jul 5. Cancer Chemother Pharmacol. 2016. PMID: 27379498 Free PMC article. Clinical Trial.
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.
Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Vijayvergia N, et al. Among authors: denlinger cs. Br J Cancer. 2020 Apr;122(9):1309-1314. doi: 10.1038/s41416-020-0775-0. Epub 2020 Mar 10. Br J Cancer. 2020. PMID: 32152503 Free PMC article. Clinical Trial.
98 results